TMPRSS2-ERG Gene Fusion Detection in Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating prostate cancer lack effective markers and targets, particularly for recurrent gene fusions that are indicative of the disease, limiting diagnostic precision and therapeutic options.
Innovation Solution
Detection of gene fusions involving androgen-regulated genes and ETS family members, such as TMPRSS2 and ERG, using various nucleic acid and protein-based techniques, along with therapeutic agents that inhibit these fusions, to provide diagnostic and therapeutic strategies for prostate cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for prostate cancer, then general screening is possible, but diagnostic precision and identification of specific molecular targets is insufficient
Solution Approach 1:
The patent segments the diagnostic approach by identifying specific gene fusion types (TMPRSS2-ERG, TMPRSS2-ETV1, etc.) and developing targeted detection methods for each fusion partner, allowing precise diagnosis through modular detection strategies rather than attempting to detect all possible fusions simultaneously
Solution Approach 2:
The patent uses FISH probes as intermediary tools that bridge the gap between complex chromosomal rearrangements and detectable signals. The probes hybridize to specific gene loci and produce fluorescent signals that indicate the presence of gene fusions, converting complex molecular events into observable diagnostic data
2Reliability
If targeted therapeutic agents are developed against specific gene fusions, then treatment effectiveness is improved, but the complexity of identifying and targeting specific fusions increases
Solution Approach 1:
The patent performs preliminary identification and classification of gene fusion types through FISH-based diagnostic testing before initiating targeted therapy. By pre-characterizing the specific fusion partner (ERG, ETV1, ETV4, FLI1), the system enables selection of appropriate targeted agents without requiring complex real-time decision-making during treatment
Solution Approach 2:
The patent changes the diagnostic parameter from general cancer detection to specific gene fusion identification. By focusing on detecting particular fusion events (TMPRSS2-ERG, TMPRSS2-ETV1, etc.), the system transforms an overwhelming complexity problem into a manageable set of discrete detection targets, each with potential therapeutic implications
Data Source
AI summary
Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.